Bio-Rad Laboratories, Inc. reported its financial results for the third quarter of 2025, revealing a slight increase in net sales to $653.0 million, up from $649.7 million in the same period last year. However, on a currency-neutral basis, sales decreased by approximately 1.7%. The company's gross profit margin also declined to 52.6% from 54.8% year-over-year, primarily due to higher material costs and reduced fixed manufacturing absorption. For the nine months ended September 30, 2025, total revenue was $1.89 billion, a decrease of 0.5% compared to $1.90 billion in the prior year.

The company experienced significant changes in profitability, reporting a net loss of $341.9 million for the third quarter, compared to a net income of $653.2 million in the same quarter of 2024. This loss was largely attributed to a $495.3 million loss from changes in the fair market value of equity securities and loan receivables, particularly related to its investment in Sartorius AG. The effective income tax rate for the quarter was 20.7%, down from 24.2% in the previous year.

In terms of strategic developments, Bio-Rad completed the acquisition of Stilla Technologies on June 30, 2025, for a total consideration of approximately $257.7 million. This acquisition is expected to enhance Bio-Rad's offerings in droplet digital PCR technology and facilitate entry into new molecular testing markets. The company also reported a restructuring plan initiated in February 2025, which is expected to improve operational efficiency but has incurred costs of $40.8 million to date.

Operationally, Bio-Rad's customer base remains diverse, with approximately 41% of year-to-date sales derived from the United States and 59% from international markets. The company noted challenges in the biopharma market and reduced government funding affecting its customer spending. As of September 30, 2025, Bio-Rad had cash, cash equivalents, and short-term investments totaling $1.4 billion, with no outstanding borrowings under its $200 million revolving credit facility. The company anticipates that its liquidity, combined with cash flow from operations, will be sufficient to meet its operational needs and strategic objectives in the coming year.

About BIO-RAD LABORATORIES, INC.

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products globally. Its Life Science segment offers instruments, reagents, and consumables for biological material analysis, serving research institutions, biopharma, and food safety markets. The Clinical Diagnostics segment provides integrated test systems and reagents for clinical laboratories worldwide. Bio-Rad’s business model emphasizes innovation, direct sales, and recurring revenue from consumables tied to installed diagnostic systems.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.